Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00547014 · ClinicalTrials.gov registry record · Phase 1
First Safety Study in Humans of a Single Dose of CPG 52364
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 61
- Enrollment target
NCT00547014 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 61 participants.
The verdict
NCT00547014, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 61 participants
- Enrollment target
Study Summary
Determine the safety and tolerability of the study drug, CPG 52364, when given as liquid or capsule. Another purpose is to determine how the drug enters and leaves the blood stream and body tissues over time.
Interventions
- DRUG Placebo Comparator: Cohort 1 Placebo
- DRUG 52364 3 mg
- DRUG Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo
- DRUG 52364 10 mg
- DRUG 52364 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00547014
The ClinicalTrials.gov registry entry for NCT00547014 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo Comparator: Cohort 1 Placebo is the first listed.
NCT00547014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00547014 about?
NCT00547014 is a clinical study titled "First Safety Study in Humans of a Single Dose of CPG 52364". Determine the safety and tolerability of the study drug, CPG 52364, when given as liquid or capsule. Another purpose is to determine how the drug enters and leaves the blood stream and body tissues over time.
What is the current status of trial NCT00547014?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 61 participants. The study started on 2007-09. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00547014?
The interventions under investigation include: Placebo Comparator: Cohort 1 Placebo (DRUG), 52364 3 mg (DRUG), Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo (DRUG), 52364 10 mg (DRUG), 52364 30 mg (DRUG).
Who is sponsoring clinical trial NCT00547014?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.